Williams C J, Barley V L, Blackledge G R, Rowland C G, Tyrrell C J, Bachelot F, Dermaille A, Fargeot P, Namer M, Pouillart J
Royal South Hants Hospital, Southampton, UK.
Clin Oncol (R Coll Radiol). 1995;7(2):87-92. doi: 10.1016/s0936-6555(05)80807-6.
Trilostane and aminoglutethimide, both given with a physiological replacement dose of hydrocortisone, were randomly allocated to 112 eligible patients with postmenopausal advanced breast cancer. Following treatment failure on either drug the patient continued with the other, if they were in a suitable clinical condition. Sixty-three patients initially received trilostane, of whom 33 subsequently received aminoglutethimide; 49 patients initially had aminoglutethimide and 14 of these then received trilostane. Both groups of patients were comparable in all respects. There was no difference in the response rate to either drug or in the average time to disease progression for the two drugs. Of the 47 patients who received both drugs, nine (19%) showed a response to both, indicating no cross-resistance. Side effects were seen to both drugs in approximately half the patients; these were mainly gastrointestinal symptoms with trilostane and rashes and drowsiness with aminoglutethimide. There was no evidence of cross-over patient susceptibility to side effects.
曲洛司坦和氨鲁米特均与生理替代剂量的氢化可的松联合使用，被随机分配给112例符合条件的绝经后晚期乳腺癌患者。如果患者处于合适的临床状态，在其中一种药物治疗失败后，继续使用另一种药物。63例患者最初接受曲洛司坦治疗，其中33例随后接受氨鲁米特治疗；49例患者最初接受氨鲁米特治疗，其中14例随后接受曲洛司坦治疗。两组患者在各方面均具有可比性。两种药物的有效率及疾病进展的平均时间均无差异。在接受两种药物治疗的47例患者中，9例（19%）对两种药物均有反应，表明不存在交叉耐药性。约一半的患者出现了两种药物的副作用；曲洛司坦的副作用主要是胃肠道症状，氨鲁米特的副作用是皮疹和嗜睡。没有证据表明患者对副作用存在交叉易感性。
